Recently, the patent rights to mRNA display technology were acquired by Bristol-Myers Squibb as a major protein design engine for the systematic development of biopharmaceuticals with high potency ...

Currently, mRNA display is a totally in vitro peptide or protein selection method. Owing to its unique features, we expect that this technique will be widely applied to investigate many different ...

After hours: February 14 at 7:59:50 PM EST Loading Chart for MRNA ...

mRNA vaccine developer Moderna (MRNA) is climbing nearly 5% in early trading today after it was awarded about $590 million by the U.S. government's Department of Health and Human Services (HHS) on ...

CureVac and partner GSK are, meanwhile, also developing an mRNA-based flu vaccine, but are a little further back in development, as their shot is in phase 1 testing.

Structural biologists provide a first-time look at the atomic level into the quality control mechanism of this complex ...

Another kind of RNA therapy that has been approved by regulators in the U.S. and Europe alike, are antisense oligonucleotides. These work by binding to specific mRNA sequences in order to modify gene ...

In a new study published recently in the journal Cell Reports, Yale researchers reveal that mRNA, or messenger RNA, plays a significant role in cell migration, a duty that also dramatically expands ...

Inhibition of nonsense-mediated decay turns immunologically cold tumors hot by increasing the amount of mutant RNA leading to an increase in T-cell-targetable neoantigens on the cell surface.